HPV vaccine acceptance, utilization and expected impacts in the U.S.: Where are we now?

Human Vaccines

Volumn 6, Issue 9, 2010, Pages 715-720

  Dempsey, Amanda F ^a   Patel, Divya A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Acceptability; Adolescents; Adults; Human papillomavirus; Utilizations; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ATTITUDE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK FACTOR; UNITED STATES; UTERINE CERVIX CANCER; VIRUS INFECTION;

EID: 78649366533     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.9.12730     Document Type: Review

References (71)

1. Centers for Disease Control and Prevention. Genital HPV Infection - CDC Fact Sheet 2004; http://www.cdc.gov/std/HPV/STDFact-HPV.htm; Accessed 2010.
2. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119:2677-84.
3. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297:813-9.
4. Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005; 191:731-8.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59:225-49.
7. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124:1626-36.
8. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24:11-25.
9. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14:467-75.
10. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8. (Pubitemid 127695953)
11. Linnehan MJ, Groce NE. Counseling and educational interventions for women with genital human papillomavirus infection. AIDS Patient Care STDS 2000; 14:439-45.
12. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines 2006. MMWR Recomm Rep 2006; 55:1-94.
13. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27:46-53.
14. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007.
15. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on All HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102:325-39.
16. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-85.
17. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix() and Gardasil(R) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2010; 5:705-19.
18. U.S. Food and Drug Administration. Product Approval Information - Licensing Action, Gardasil 2006; http://www.fda.gov/cber/products/ hpvmer060806qa.htm; Accessed 2006.
19. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
20. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis 2004; 38:1440-6.
21. U.S. Food and Drug Administration. FDA News Release: FDA Approves New Indication for Gardasil to Prevent Genital warts in Men and Boys 2009; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187003.htm; Accessed 2009.
22. Mitchell D. ACIP Supports "Permissive" Use, But Not Routine Use, of Gardasil in Males 2009; http://www.aafp.org/online/en/home/publications/ news/newsnow/clinical-care-research/20091027acip-hpv-vacc.html; Accessed 2009.
23. Davis MM, Ndiaye SM, Freed GL, Kim CS, Clark SJ. Influence of insurance status and vaccine cost on physicians' administration of pneumococcal conjugate vaccine. Pediatrics 2003; 112:521-6.
24. U.S. Food and Drug Administration. FDA News Release: FDA approves new vaccine for prevention of cervical cancer 2009; http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm187048.htm; Accessed November 30th 2009.
25. th 2010.
26. Lee GM, Santoli JM, Hannan C, Messonnier ML, Sabin JE, Rusinak D, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA 2007; 298:638-43.
27. National, state and local area vaccination coverage among adolescents aged 13-17 years - United States 2008. MMWR Morb Mortal Wkly Rep 2009; 58:997-1001.
28. Bach P. Gardasil: From bench, to bedside, to blunder. Lancet 2010; 375:963-4.
29. Dempsey A, Cohn L, Dalton VA, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a unveristy-based health system. Vaccine 2010; 28:989-95.
30. Eggerston L. Three provinces to study 2-dose HPV vaccine. CMAJ 2007; 177:444-5.
31. Reiter PL, Brewer NT, Gottlieb SL, McRee AL, Smith JS. Parents' health beliefs and HPV vaccination of their adolescent daughters. Soc Sci Med 2009; 69:475-80.
32. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clin Proc 2009; 84:864-70.
33. Gottlieb SL, Brewer NT, Sternberg MR, Smith JS, Ziarnowski K, Liddon N, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health 2009; 45:430-7.
34. Neubrand TP, Radecki Breitkopf C, Rupp R, Brieitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clin Pediatr (Phila) 2009; 48:966-9.
35. Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI, Glynn S, et al. Human Papillomavirus Vaccine Uptake, Predictors of Vaccination and Self-Reported Barriers to Vaccination. J Womens Health (Larchmt) 2009; 18:1679-86.
36. Rosenthal SL, Rupp R, Zimet GD, Meza HM, Loza ML, Short MB, et al. Uptake of HPV vaccine: demographics, sexual history and values, parenting style and vaccine attitudes. J Adolesc Health 2008; 43:239-45.
37. Brotherton JM, Deeks SL, Campbell-Lloyd S, Misrachi A, Passaris I, Peterson K, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell 2008; 32:457-61.
38. Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 2009; 48:426-31.
39. Rosenthal SL, Weiss TW, Zimet GD, Ma L, Good MB, Vichnin MD. Predictors of HPV vaccine uptake among women aged 19-26: Importance of a physician's recommendation. Vaccine; Epub Jan 4 2010.
40. Dempsey A, Cohn L, Dalton VA, Ruffin M. HPV vaccine utilization among women 19-26 years in a University-based health system. Under review 2010.
41. Licht AS, Murphy JM, Hyland AJ, Fix BV, Hawk LW, Mahoney MC. Is use of the HPV vaccine among female college students related to HPV knowledge and risk perception? Sex Transm Infect 2009.
42. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Prev Med 2007; 45:107-14.
43. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the Reasons Why Mothers Do or Do Not Have Their Adolescent Daughters Vaccinated Against Human Papillomavirus. Ann Epidemiol [Epub ahead of print] 2009; 19:531-8.
44. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health. Nov 2009; 45:453-62.
45. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006; 117:1486-93.
46. English A, Shaw FE, McCauley MM, Fishbein DB. Legal basis of consent for health care and vaccination for adolescents. Pediatrics 2008; 121:85-7.
47. McManus M, Brauer M, Weader R, Newacheck P. The adequacy of college health insurance coverage. J Am Coll Health 1991; 39:177-85.
48. Licht AS, Murphy JM, Hyland AJ, Fix BV, Hawk LW, Mahoney MC. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception? Sex Transm Infect 2010; 86:74-8.
49. Roberts ME, Gerrard M, Reimer R, Gibbons FX. Mother-daughter communication and human papillomavirus vaccine uptake by college students. Pediatrics 125:982-9.
50. Gerend MA, Barley J. Human Papillomavirus Vaccine Acceptability Among Young Adult Men. Sex Transm Dis 2009; 36:58-62.
51. Reiter PL, Brewer NT, Smith JS. HPV Knowledge and HPV Vaccine Acceptability among a National Sample of Heterosexual Males. Sex Transm Infect 2009.
52. Ferris DG, Waller JL, Miller J, Patel P, Price GA, Jackson L, et al. Variables Associated With Human Papillomavirus (HPV) Vaccine Acceptance by Men. J Am Board Fam Med 2009; 22:34-42.
53. Jones M, Cook R. Intent to receive an HPV vaccine among university men and women and implications for vaccine administration. J Am Coll Health 2008; 57:23-32.
54. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS. Acceptability of HPV Vaccine Among a National Sample of Gay and Bisexual Men. Sex Transm Dis 2010.
55. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 2005; 37:248-51.
56. Slomovitz BM, Sun CC, Frumovitz M, et al. Are women ready for the HPV vaccine? Gynecol Oncol 2006; 103:151-4.
57. Watts LA, Joseph N, Wallace M, Rauh-Hain JA, Muzikansky A, Growdon WB, et al. HPV vaccine: A comparison of attitudes and behavioral perspectives between Latino and non-Latino women. Gynecol Oncol 2009; [Epub ahead of print].
58. Dempsey A, Butchart A, Singer D, Clark SJ, Davis MM. Factors associated with parental intentions for male human papillomavirus vaccination: results of a national survey. Under review 2010.
59. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008; 26:76-86.
60. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28:88-100.
61. Schiffman M. Integration of human papillomavirus vaccination, cytology and human papillomavirus testing. Cancer 2007; 111:145-53.
62. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24:178-86.
63. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003; 106:896-904.
64. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-15.
65. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13:631-9.
66. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-9.
67. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9:37-48.
68. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
69. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008; 14:244-51.
70. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-32.
71. Dempsey A, Mendez D. Model of parental opinions and HPV vaccine utilization among adolescents: Impact of an HPV vaccine school mandate. J Adolesc Health 2010; Epub ahead of print.